The Economic Times
English EditionEnglish Editionहिंदी संस्करण
| 06 April, 2021, 09:11 AM IST | E-Paper
Search
+

    Diagnostics counters likely to witness windfall gains

    “Earnings trajectory of chains won’t dramatically change earnings picture. It is more of a portfolio shifting that is happening,” said Bhandari.

    Synopsis

    Analysts said diagnostics companies will benefit from the marginal costs of doing Covid detection tests. With a partial lockdown, non-Covid tests can be carried out more smoothly as opposed to a situation where there is a complete restriction on outdoor movement.

    Mumbai: Shares of diagnostics companies jumped amid Monday's sell-off on expectations rising Covid-19 cases will boost testing. Money managers said investors are shuffling their portfolios in favour of companies which benefit from essential services than discretionary spends. Thyrocare Technologies surged 7.35 per cent at Rs 1,014.6 and Metropolis Healthcare gained 2.6 per cent to close at Rs 2,220. Dr Lal PathLabs jumped 6.1 per cent to Rs
    Share This Article
    • GIFT ARTICLE
    • FONT SIZE
    • SAVE
    • COMMENT

    Sign in to read the full article

    You’ve got this Prime Story as a Free Gift

    Special Offer on ET Prime

    Subscribe to ET Prime - Get Flat 20% Off

    View Plans

    Special Offer on ET Prime

    Subscribe & get 30% off on 2-Year Plan

    View Plans

    Special Offer on ET Prime

    Subscribe & get 30% off on 2-Year Plan

    View Plans

    Why ?

    • Sharp Insight-rich, Indepth stories across 20+ sectors

    • Access the exclusive Economic Times stories, Editorial and Expert opinion

    • Clean experience with
      Minimal Ads
    • Comment & Engage with ET Prime community
    • Exclusive invites to Virtual Events with Industry Leaders
    • A trusted team of Journalists & Analysts who can best filter signal from noise
    The Economic Times